Heads of state from Brazil, Russia, India, China, and South Africa (BRICS), gathered in Ufa, Rus
Statements and Press Releases
WASHINGTON, D.C. – August 11, 2015 – The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) has joined The Onchocerciasis Vaccine for Africa (TOVA) Initiative, which was established this year to develop and test a vaccine for onchocerciasis. Also known as river blindness, onchocerciasis infects an estimated 17 million people, with more than 99 percent of these cases spread throughout 31 countries in sub-Saharan Africa. Approximately 169 million people are at risk of contracting this disease.
LONDON — July 30, 2015 — Sabin Foundation Europe (SFE), the UK partner of the Sabin Vaccine Institute (Sabin), today announced the election of Ms. Cecile Hillary, managing director at Morgan Stanley and co-head of debt capital markets for financial institutions in Europe, to the SFE Board of Trustees.
WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.